Director / Senior Director, DMPK

formationbio; Boston (MA); Presencial; USD 180.000 - 260.000; Tempo integral

Resumo da vaga

Formation Bio is seeking an experienced Director of Drug Metabolism and Pharmacokinetics (DMPK) to lead scientific and strategic efforts across our development portfolio. The role combines diligence for potential in-licensing and acquisitions with DMPK leadership for preclinical and clinical programs, integrating data to guide development decisions.

The ideal candidate will deeply understand PK, ADME, metabolism, and exposure–response relationships, contribute to cross-functional teams, and

Qualificações

• Deep DMPK expertise and drug-development judgment.
• Experience evaluating nonclinical and clinical PK/PD data for diligence and licensing.
• Ability to integrate DMPK findings with pharmacology, toxicology, clinical, CMC, and regulatory information.

Responsabilidades

• Serve as the DMPK expert for diligence of licensing, acquisition, and partnerships across therapeutic areas.
• Evaluate nonclinical and clinical PK/ADME/metabolism data to assess asset strength and risks.
• Assess data quality, identify gaps, and distinguish material risks from addressable issues.
• Develop fit-for-purpose DMPK strategies from late preclinical through IND/CTA and early clinical development.
• Lead cross-functional DMPK leadership on programs and decision-making.

Conhecimentos

DMPK expertise

PK/PD analysis

DMPK diligence

Cross-functional leadership

Drug development

Ferramentas

PK modeling

Data analysis

Regulatory submissions

Descrição da vaga

About Formation Bio

Formation Bio is a tech and AI driven pharma company differentiated by radically more efficient drug development.

Advancements in AI and drug discovery are creating more candidate drugs than the industry can progress because of the high cost and time of clinical trials. Recognizing that this development bottleneck may ultimately limit the number of new medicines that can reach patients, Formation Bio, founded in 2016 as TrialSpark Inc., has built technology platforms, processes, and capabilities to accelerate all aspects of drug development and clinical trials. Formation Bio partners, acquires, or in-licenses drugs from pharma companies, research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to bring new medicines to patients. The company is backed by investors across pharma and tech, including a16z, Sequoia, Sanofi, Thrive Capital, John Doerr, Spark Capital, SV Angel Growth, and others.

You can read more at the following links:

Our Vision for AI in Pharma

Our Current Drug Portfolio

Our Technology & Platform

At Formation Bio, our values are the driving force behind our mission to revolutionize the pharma industry. Every team and individual at the company shares these same values, and every team and individual plays a key part in our mission to bring new treatments to patients faster and more efficiently.

About the Position

Formation Bio is seeking an experienced Director of Drug Metabolism and Pharmacokinetics (DMPK) to provide scientific and strategic leadership across our growing portfolio of development-stage therapeutics.

This role will have two important areas of responsibility. First, the Director will serve as a DMPK expert in the evaluation and diligence of potential in-licensing and acquisition opportunities, rapidly assessing the quality of available data, identifying key risks and uncertainties, and developing a clear view of an asset's pharmacokinetic, translational, and clinical potential. Second, the Director will provide DMPK leadership for programs in our advanced preclinical and clinical pipeline, integrating nonclinical and clinical data to support development strategy, dose selection, clinical pharmacology, and regulatory decision-making.

The ideal candidate combines deep technical expertise in DMPK with excellent drug-development judgment. They are equally comfortable digging into source data during a fast-moving diligence process, developing a quantitative understanding of an asset's PK and exposure-response relationships, and representing DMPK on a multidisciplinary development team.

This is a highly cross-functional role with the opportunity to influence both which medicines Formation Bio brings into its portfolio and how we develop them.

Responsibilities

• Serve as the DMPK subject-matter expert for scientific diligence of potential in-licensing, acquisition, and partnership opportunities across a range of therapeutic areas and stages of development.
• Rapidly evaluate nonclinical and clinical PK (in collaboration with Clinical Pharmacology), ADME, metabolism, transporter, bioavailability, PK/PD, and exposure-response datasets to assess an asset's strengths, liabilities, and development potential.
• Critically assess the quality and completeness of available data, identify important gaps or inconsistencies, and distinguish issues that represent material development risks from those that can be readily addressed.
• Evaluate human PK characteristics, dose and exposure projections, therapeutic margins, DDI potential, organ impairment considerations, formulation and absorption issues, and other factors that may affect an asset's clinical profile.
• Integrate DMPK findings with pharmacology, toxicology, clinical, CMC, and regulatory information to develop a holistic assessment of an asset.
• Develop clear, decision-oriented recommendations for cross-functional diligence teams and senior leadership, including articulation of key risks, uncertainties, potential mitigations, and value-creating opportunities.
• Define priority experiments, analyses, or data requests needed to resolve critical questions during diligence and transition promising assets into the Formation Bio portfolio.

Preclinical & Clinical Development

• Provide DMPK leadership for advanced preclinical and clinical-stage programs, serving as the DMPK representative on cross-functional development teams.
• Develop fit-for-purpose DMPK strategies from late preclinical development through IND/CTA, early clinical development, and subsequent stages of development.
• Integrate in vitro ADME, animal PK, toxicokinetics, clinical PK, pharmacology, biomarker, and safety data to develop a quantitative understanding of exposure and response.
• Lead human PK prediction and nonclinical-to-clinical PK/PD translation to inform FiH dose selection, and partner with Clinical Pharmacology and Pharmacometrics to support clinical dose escalation and dose optimiza